Adtalem Global Education Inc. (NYSE:CVSA – Get Free Report) CEO Stephen Beard sold 3,545 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $130.34, for a total transaction of $462,055.30. Following the transaction, the chief executive officer owned 415,197 shares in the company, valued at $54,116,776.98. The trade was a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Adtalem Global Education Price Performance
Shares of CVSA stock traded up $3.98 during midday trading on Thursday, reaching $132.20. 267,402 shares of the company traded hands, compared to its average volume of 371,319. The business’s 50 day moving average price is $125.00. Adtalem Global Education Inc. has a 1-year low of $86.97 and a 1-year high of $156.26. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. The stock has a market cap of $4.50 billion, a price-to-earnings ratio of 18.78, a PEG ratio of 0.94 and a beta of 0.62.
Adtalem Global Education (NYSE:CVSA – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.90 by $0.19. Adtalem Global Education had a return on equity of 20.88% and a net margin of 12.87%.The business had revenue of $501.38 million for the quarter. Adtalem Global Education has set its FY 2027 guidance at 8.900-9.150 EPS. As a group, research analysts anticipate that Adtalem Global Education Inc. will post 8.99 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several analysts have weighed in on CVSA shares. Barrington Research reissued an “outperform” rating and issued a $170.00 target price on shares of Adtalem Global Education in a report on Monday, June 8th. Truist Financial boosted their price objective on shares of Adtalem Global Education from $130.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Wall Street Zen raised shares of Adtalem Global Education from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Adtalem Global Education in a report on Friday, May 22nd. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $155.00.
Get Our Latest Stock Report on Adtalem Global Education
Adtalem Global Education Company Profile
Adtalem Global Education (NYSE: CVSA) is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.
Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.
Featured Stories
- Five stocks we like better than Adtalem Global Education
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Adtalem Global Education Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adtalem Global Education and related companies with MarketBeat.com's FREE daily email newsletter.
